[{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ZKAB001","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lee Pharma \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lee Pharma \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lee Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14000000000000001,"dosageForm":"Infusion","sponsorNew":"Lee Pharma \/ Lee Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Lee Pharma \/ Lee Pharma"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mizoribine","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mizoribine","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH) | GMP synthase [glutamine-hydrolyzing]","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irsogladine Maleate","moa":"Gap junctions\/Unknown","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Undisclosed","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gimatecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gimatecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gimatecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Lee Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.080000000000000002,"dosageForm":"Powder for Inhalation","sponsorNew":"Lee Pharma \/ Lee Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Lee Pharma \/ Lee Pharma"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AU409","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"CSIR-Indian Institute of Chemical Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"2-Deoxy-D-Glucose","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Lee Pharma \/ Lee Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Lee Pharma \/ Lee Pharma"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Prasterone","moa":"steroids (androgens","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ZKAB001","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Socazolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human Interferon Alpha-2b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Lucinactant","moa":"pulmonary surfactants; tachykinin (neurokinin) receptor antagonists","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lee Pharma \/ Lee Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Lee Pharma \/ Lee Pharma"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Socazolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ZKAB001","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Socazolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ZKAB001","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lee Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anfibatide","moa":"Platelet glycoprotein Ib alpha chain","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lee Pharma \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Lee Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
KEY PRODUCTS
Reset All
Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.
